Inhalerx Ltd (IRX) - Net Assets

Latest as of June 2025: AU$-877.11K AUD ≈ $-620.61K USD

Based on the latest financial reports, Inhalerx Ltd (IRX) has net assets worth AU$-877.11K AUD (≈ $-620.61K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.44 Million ≈ $1.02 Million USD) and total liabilities (AU$2.31 Million ≈ $1.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$-877.11K
% of Total Assets	-61.07%
Annual Growth Rate	N/A
5-Year Change	-104.83%
10-Year Change	N/A
Growth Volatility	123.45

Inhalerx Ltd - Net Assets Trend (2016–2024)

This chart illustrates how Inhalerx Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Inhalerx Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Inhalerx Ltd (2016–2024)

The table below shows the annual net assets of Inhalerx Ltd from 2016 to 2024. For live valuation and market cap data, see IRX stock market capitalisation.

Year	Net Assets	Change
2024-12-31	AU$-63.97K ≈ $-45.26K	-109.61%
2023-12-31	AU$665.47K ≈ $470.86K	-65.03%
2022-12-31	AU$1.90 Million ≈ $1.35 Million	-28.94%
2021-12-31	AU$2.68 Million ≈ $1.89 Million	+102.27%
2020-12-31	AU$1.32 Million ≈ $936.76K	+289.29%
2019-12-31	AU$340.08K ≈ $240.63K	-87.32%
2018-12-31	AU$2.68 Million ≈ $1.90 Million	-40.47%
2017-12-31	AU$4.51 Million ≈ $3.19 Million	-38.50%
2016-12-31	AU$7.33 Million ≈ $5.19 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Inhalerx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1403017000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	AU$14.53 Million	%
Other Comprehensive Income	AU$-212.62K	%
Total Equity	AU$-63.97K	100.00%

Inhalerx Ltd Competitors by Market Cap

The table below lists competitors of Inhalerx Ltd ranked by their market capitalization.

Company	Market Cap
Beowulf Mining PLC ST:BEO-SDB	$4.18 Million
Anagenics Ltd AU:AN1	$4.18 Million
Henderson International Income Trust PLC LSE:HINT	$4.18 Million
EPRCOMUNICAZIONE S.P.A. F:J3P	$4.19 Million
ASIA Capital Group Public Company Limited BK:ACAP	$4.18 Million
Fastpasscorp A/S CO:FASTPC	$4.18 Million
Cosmo Metals Ltd AU:CMO	$4.18 Million
Sulliden Minerals SA TO:SMC	$4.17 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Inhalerx Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 665,471 to -63,966, a change of -729,437 (-109.6%).
Net loss of 1,276,087 reduced equity.
Share repurchases of 6,350 reduced equity.
Other comprehensive income increased equity by 28,730.
Other factors increased equity by 524,270.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	AU$-1.28 Million	-1994.95%
Share Repurchases	AU$6.35K	-9.93%
Other Comprehensive Income	AU$28.73K	+44.91%
Other Changes	AU$524.27K	+819.61%
Total Change	AU$-	-109.61%

Book Value vs Market Value Analysis

This analysis compares Inhalerx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	AU$0.27	AU$0.02	x
2017-12-31	AU$0.06	AU$0.02	x
2018-12-31	AU$0.03	AU$0.02	x
2019-12-31	AU$0.00	AU$0.02	x
2020-12-31	AU$0.01	AU$0.02	x
2021-12-31	AU$0.02	AU$0.02	x
2022-12-31	AU$0.01	AU$0.02	x
2023-12-31	AU$0.00	AU$0.02	x
2024-12-31	AU$0.00	AU$0.02	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Inhalerx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -380.81%
• Asset Turnover: 0.47x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-139.77%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-4.76%	-34976.31%	0.00x	1.17x	AU$-1.08 Million
2017	-46.49%	-424.69%	0.10x	1.13x	AU$-2.55 Million
2018	-69.89%	-542.20%	0.11x	1.15x	AU$-2.14 Million
2019	-702.10%	-5124.00%	0.07x	1.83x	AU$-2.42 Million
2020	-76.39%	-1037.33%	0.05x	1.44x	AU$-1.14 Million
2021	-41.49%	-664.15%	0.06x	1.09x	AU$-1.38 Million
2022	-99.95%	-7770.36%	0.01x	1.17x	AU$-2.12 Million
2023	-216.88%	-119.87%	0.76x	2.37x	AU$-1.51 Million
2024	0.00%	-380.81%	0.47x	0.00x	AU$-1.27 Million

Industry Comparison

This section compares Inhalerx Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $9,810,720
Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Inhalerx Ltd (IRX)	AU$-877.11K	-4.76%	N/A	$4.18 Million
Adalta Ltd (1AD)	$3.70 Million	-162.25%	0.87x	$6.50 Million
Algorae Pharmaceuticals Ltd (1AI)	$-1.33 Million	0.00%	0.00x	$20.04 Million
ACRUX Ltd (ACR)	$12.85 Million	-73.71%	0.44x	$3.20 Million
Actinogen Medical Ltd (ACW)	$21.74 Million	-43.69%	0.07x	$105.70 Million
Argenica Therapeutics Ltd (AGN)	$13.95 Million	-39.28%	0.17x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$11.03 Million	-40.87%	0.23x	$58.08 Million
Anatara Lifesciences Ltd (ANR)	$924.54K	-218.83%	0.54x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$20.73 Million	-6.40%	0.01x	$76.95 Million
Amplia Therapeutics Ltd (ATX)	$11.23 Million	-30.16%	0.02x	$50.82 Million
Avecho Biotechnology Ltd (AVE)	$3.27 Million	-95.48%	0.53x	$28.59 Million

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#28669 Global

#1620 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.05

All Time High

AU$0.39